Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Sonneveld P, De Wit E, Moreau P.

Crit Rev Oncol Hematol. 2017 Apr;112:153-170. doi: 10.1016/j.critrevonc.2017.02.007. Epub 2017 Feb 14. Review.

2.

Carfilzomib boosted combination therapy for relapsed multiple myeloma.

Steiner RE, Manasanch EE.

Onco Targets Ther. 2017 Feb 15;10:895-907. doi: 10.2147/OTT.S102756. eCollection 2017. Review.

3.

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S.

Ther Adv Hematol. 2017 Feb;8(2):55-70. doi: 10.1177/2040620716680548. Epub 2016 Dec 9. Review.

4.

The role of the proteasome in AML.

Csizmar CM, Kim DH, Sachs Z.

Blood Cancer J. 2016 Dec 2;6(12):e503. doi: 10.1038/bcj.2016.112. Review.

5.

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Franken B, van de Donk NW, Cloos JC, Zweegman S, Lokhorst HM.

Ther Adv Hematol. 2016 Dec;7(6):330-344. Epub 2016 Sep 13. Review.

6.

Recent advances in multiple myeloma: a Korean perspective.

Hong J, Lee JH.

Korean J Intern Med. 2016 Sep;31(5):820-34. doi: 10.3904/kjim.2015.408. Epub 2016 Sep 1. Review.

7.

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.

Lee HS, Min CK.

Korean J Intern Med. 2016 Sep;31(5):809-19. doi: 10.3904/kjim.2016.110. Epub 2016 Sep 1. Review.

8.

Current Trends of Renal Impairment in Multiple Myeloma.

Yadav P, Cook M, Cockwell P.

Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3. Review.

9.

The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China.

Shi H, Chen Z, Xie J, Chen N.

Kidney Dis (Basel). 2016 Mar;1(4):235-40. doi: 10.1159/000443492. Epub 2016 Jan 21. Review.

10.

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.

Zou Y, Ma X, Yu H, Hu C, Fan L, Ran X.

Oncotarget. 2017 Jun 13;8(24):39805-39817. doi: 10.18632/oncotarget.10768. Review.

11.

Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.

Guedes RA, Serra P, Salvador JA, Guedes RC.

Molecules. 2016 Jul 16;21(7). pii: E927. doi: 10.3390/molecules21070927. Review.

12.

Novel agents in the treatment of multiple myeloma: a review about the future.

Naymagon L, Abdul-Hay M.

J Hematol Oncol. 2016 Jun 30;9(1):52. doi: 10.1186/s13045-016-0282-1. Review.

13.

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402. Review.

14.

Treatment of relapsed and refractory multiple myeloma.

Sonneveld P, Broijl A.

Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189. Review.

15.

The effects of proteasome inhibitors on bone remodeling in multiple myeloma.

Zangari M, Suva LJ.

Bone. 2016 May;86:131-8. doi: 10.1016/j.bone.2016.02.019. Epub 2016 Mar 3. Review.

16.

Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.

Chao A, Wang TH.

Taiwan J Obstet Gynecol. 2016 Feb;55(1):3-8. doi: 10.1016/j.tjog.2015.12.004. Review.

17.

Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK.

Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016. Review.

18.

Multiple Myeloma: Diagnosis and Treatment.

Rajkumar SV, Kumar S.

Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007. Review.

19.

Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O.

Pharmacotherapy. 2015 Dec;35(12):1173-88. doi: 10.1002/phar.1671. Review.

20.

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.

Dimopoulos MA, Kastritis E, Ghobrial IM.

Ann Oncol. 2016 Feb;27(2):233-40. doi: 10.1093/annonc/mdv572. Epub 2015 Nov 23. Review.

Supplemental Content

Loading ...
Support Center